332 related articles for article (PubMed ID: 35581611)
1. Complete response to combination therapy using nivolumab and ipilimumab for metastatic, sarcomatoid collecting duct carcinoma presenting with high expression of programmed death-ligand 1: a case report.
Fuu T; Iijima K; Kusama Y; Otsuki T; Kato H
J Med Case Rep; 2022 May; 16(1):193. PubMed ID: 35581611
[TBL] [Abstract][Full Text] [Related]
2. The Role of Cytoreductive Nephrectomy in Renal Cell Carcinoma with Sarcomatoid Histology: A Case Series and Review of the Literature.
Studentova H; Rusarova N; Ondruskova A; Zemankova A; Student V; Skanderova D; Melichar B
Curr Oncol; 2022 Aug; 29(8):5475-5488. PubMed ID: 36005171
[TBL] [Abstract][Full Text] [Related]
3. Sarcomatoid urothelial carcinoma of the renal pelvis treated with immunotherapy.
Anraku T; Hashidate H; Nakahara A; Imai T; Kawakami Y
BMC Urol; 2023 Mar; 23(1):38. PubMed ID: 36934227
[TBL] [Abstract][Full Text] [Related]
4. Salvage ipilimumab associated with a significant response in sarcomatoid renal cell carcinoma.
George G; Schmidt L; Tolat P; Riese M; Kilari D
J Immunother Cancer; 2020 Feb; 8(1):. PubMed ID: 32114501
[TBL] [Abstract][Full Text] [Related]
5. Differential treatment responses to immune checkpoint inhibitor (ICI) therapy in a case of multiple primary malignancies: the programmed death ligand-1 (PD-L1) negative ureteral and lung metastasis from a clear cell renal cell carcinoma appearing after robotic-assisted partial nephrectomy progressed after ICI therapy, while synchronous PD-L1-positive primary lung squamous cell carcinoma responded very well to ICI therapy: a case report.
Urushibara M; Ishizaka K; Matsutani N; Takahashi M; Nagata M; Okumura T; Matsumoto Y; Tatsuoka S; Nenohi T; Amemiya T; Shimizu Y; Shirakawa T; Kato D
World J Surg Oncol; 2023 Feb; 21(1):37. PubMed ID: 36747242
[TBL] [Abstract][Full Text] [Related]
6. Nivolumab therapy for metastatic collecting duct carcinoma after nephrectomy: A case report.
Yasuoka S; Hamasaki T; Kuribayashi E; Nagasawa M; Kawaguchi T; Nagashima Y; Kondo Y
Medicine (Baltimore); 2018 Nov; 97(45):e13173. PubMed ID: 30407350
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of tumor microenvironment and biomarkers of immune checkpoint inhibitor response in metastatic renal cell carcinoma.
Brown LC; Zhu J; Desai K; Kinsey E; Kao C; Lee YH; Pabla S; Labriola MK; Tran J; Dragnev KH; Tafe LJ; Dayyani F; Gupta RT; McCall S; George DJ; Glenn ST; Nesline MK; George S; Zibelman M; Morrison C; Ornstein MC; Zhang T
J Immunother Cancer; 2022 Oct; 10(10):. PubMed ID: 36252996
[TBL] [Abstract][Full Text] [Related]
8. Nivolumab plus ipilimumab induced endocrinopathy and acute interstitial nephritis in metastatic sarcomatoid renal-cell carcinoma: A case report and review of literature.
Hino C; Nishino K; Pham B; Jeon WJ; Nguyen M; Cao H
Front Immunol; 2022; 13():993622. PubMed ID: 36052087
[TBL] [Abstract][Full Text] [Related]
9. A case of multiple metastatic sarcomatoid renal cell carcinoma with complete response to nivolumab.
Tomioka M; Nakane K; Ozawa K; Iinuma K; Suzui N; Miyazaki T; Koie T
Cancer Rep (Hoboken); 2021 Aug; 4(4):e1356. PubMed ID: 33656804
[TBL] [Abstract][Full Text] [Related]
10. Myocarditis as an immune-related adverse event following treatment with ipilimumab and nivolumab combination therapy for metastatic renal cell carcinoma: a case report.
Miyauchi Y; Naito H; Tsunemori H; Tani R; Hasui Y; Miyake Y; Minamino T; Ishikawa R; Kushida Y; Haba R; Sugimoto M
J Med Case Rep; 2021 Oct; 15(1):508. PubMed ID: 34649593
[TBL] [Abstract][Full Text] [Related]
11. Salvage Ipilimumab and Nivolumab in Patients With Metastatic Renal Cell Carcinoma After Prior Immune Checkpoint Inhibitors.
Gul A; Stewart TF; Mantia CM; Shah NJ; Gatof ES; Long Y; Allman KD; Ornstein MC; Hammers HJ; McDermott DF; Atkins MB; Hurwitz M; Rini BI
J Clin Oncol; 2020 Sep; 38(27):3088-3094. PubMed ID: 32491962
[TBL] [Abstract][Full Text] [Related]
12. Fatal hyperprogression induced by nivolumab in metastatic renal cell carcinoma with sarcomatoid features: a case report.
Dionese M; Pierantoni F; Maruzzo M; Bimbatti D; Deppieri FM; Maran M; Gardiman MP; Basso U
Anticancer Drugs; 2021 Feb; 32(2):222-225. PubMed ID: 32868643
[TBL] [Abstract][Full Text] [Related]
13. Long-term outcomes with nivolumab plus ipilimumab versus sunitinib in first-line treatment of patients with advanced sarcomatoid renal cell carcinoma.
Rini BI; Signoretti S; Choueiri TK; McDermott DF; Motzer RJ; George S; Powles T; Donskov F; Tykodi SS; Pal SK; Gupta S; Lee CW; Jiang R; Tannir NM
J Immunother Cancer; 2022 Dec; 10(12):. PubMed ID: 36549781
[TBL] [Abstract][Full Text] [Related]
14. A Pathological Complete Response to the Combination of Ipilimumab and Nivolumab in a Patient with Metastatic Renal Cell Carcinoma.
Studentova H; Zemankova A; Spisarova M; Skanderova D; Tudos Z; Melichar B; Student V
Medicina (Kaunas); 2022 Feb; 58(3):. PubMed ID: 35334512
[No Abstract] [Full Text] [Related]
15. FRACTION-RCC: nivolumab plus ipilimumab for advanced renal cell carcinoma after progression on immuno-oncology therapy.
Choueiri TK; Kluger H; George S; Tykodi SS; Kuzel TM; Perets R; Nair S; Procopio G; Carducci MA; Castonguay V; Folefac E; Lee CH; Hotte SJ; Miller WH; Saggi SS; Lee CW; Desilva H; Bhagavatheeswaran P; Motzer RJ; Escudier B
J Immunother Cancer; 2022 Nov; 10(11):. PubMed ID: 36328377
[TBL] [Abstract][Full Text] [Related]
16. Durable disease control and refractory bullous pemphigoid after immune checkpoint inhibitor discontinuation in metastatic renal cell carcinoma: A case report.
Mari R; Guerin M; Vicier C; Walz J; Bonnet N; Pignot G; Gravis G
Front Immunol; 2022; 13():984132. PubMed ID: 36189265
[TBL] [Abstract][Full Text] [Related]
17. Tailored Immunotherapy Approach With Nivolumab in Advanced Transitional Cell Carcinoma.
Grimm MO; Schmitz-Dräger BJ; Zimmermann U; Grün CB; Baretton GB; Schmitz M; Foller S; Leucht K; Schostak M; Zengerling F; Schumacher U; Loidl W; Meran J
J Clin Oncol; 2022 Jul; 40(19):2128-2137. PubMed ID: 35275706
[TBL] [Abstract][Full Text] [Related]
18. Case report: Complete remission of bone metastasis from renal cell carcinoma in histopathological examination after treatment with immune checkpoint inhibitors.
Asano Y; Yamamoto N; Hayashi K; Takeuchi A; Miwa S; Igarashi K; Higuchi T; Taniguchi Y; Morinaga S; Horimoto T; Nakai M; Kadono Y; Nojima T; Tsuchiya H
Front Immunol; 2022; 13():980456. PubMed ID: 36238308
[TBL] [Abstract][Full Text] [Related]
19. Pathological eradication of recurrent metastatic renal cell carcinoma with sarcomatoid component by nivolumab plus ipilimumab combination therapy.
Sejima T; Masago T; Yoshida M; Nishi T; Kawabata Y; Tajima Y; Yumioka T; Honda M; Takenaka A
Int Cancer Conf J; 2021 Oct; 10(4):285-289. PubMed ID: 34567939
[TBL] [Abstract][Full Text] [Related]
20. Complete response to combination therapy with nivolumab and ipilimumab for metastatic collecting duct carcinoma of the kidney.
Watanabe K; Sugiyama T; Otsuka A; Miyake H
Int Cancer Conf J; 2020 Jan; 9(1):32-35. PubMed ID: 31950015
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
